All In Biotech

BLA 017016 · Ferring

Chorionic Gonadotropin

Gonadotropin, Chorionic · Injection

Last checked: Nov 20, 2026Latest source record: May 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Jan 15, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,292

340 Phase 3, 113 recruiting

FAERS reports

1,179

748 serious, 30 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2025.

INDICATIONS AND USAGE HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR "NORMAL" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 15, 1974 Original approval · Type 5 - New Formulation or New Manufacturer
6 products under this application
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 10,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 2,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 5,000 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 20,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued
  • CHORIONIC GONADOTROPIN · GONADOTROPIN, CHORIONIC 15,000 UNITS/VIAL · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Gonadotropin" as an intervention, any sponsor and status, largest first.

All 1,292 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ovarian hyperstimulation syndrome244
  • drug ineffective94
  • nausea74
  • off label use68
  • abdominal distension60
  • headache60
  • dyspnoea51
  • ascites50
  • vomiting44
  • abortion spontaneous41
  • pain40
  • fatigue39

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200527
200628
200745
200820
200929
201027
201153
201281
201322
201418
20159
201644
201728
201851
201988
202056
202174
2022121
2023114
202472
202580
202683

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Chorionic Gonadotropin (Chorionic Gonadotropin, Human)

2024 spending

$481K

Beneficiaries

146

598 claims

Per beneficiary

$3,291

$295.34 per unit

View as table
YearSpending
2020$460,023
2021$387,422
2022$450,809
2023$565,015
2024$480,519

Part B: Chorionic Gonadotropin* (Chorionic Gonadotropin, Human*) · HCPCS J0725

2024 spending

$337K

Beneficiaries

241

6,848 claims

Per beneficiary

$1,398

2024 ASP limit $21.87 per unit

View as table
YearSpending
2020$398,283
2021$504,301
2022$416,524
2023$327,448
2024$336,980

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,168 on PubMed

Sponsor: Ferring

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.